Richard B Lock Selected Research

Glucocorticoid Receptor Deficiency

1/2022	PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia.
12/2018	Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
10/2010	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
5/2007	Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia.
3/2005	Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard B Lock Research Topics

Disease

45	Neoplasms (Cancer) 01/2022 - 12/2003
45	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 06/2002
41	Leukemia 01/2022 - 06/2002
11	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2021 - 10/2011
10	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 04/2007
6	Neuroblastoma 01/2016 - 11/2007
5	Glucocorticoid Receptor Deficiency 01/2022 - 03/2005
4	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 01/2012
3	Ewing Sarcoma (Sarcoma, Ewing) 02/2015 - 11/2011
2	Philadelphia Chromosome 11/2021 - 01/2020
2	Carcinogenesis 06/2014 - 04/2013
2	Lymphoma (Lymphomas) 05/2009 - 12/2003
2	Acute Promyelocytic Leukemia 01/2008 - 04/2007
1	Rheumatoid Arthritis 01/2021
1	Acute Erythroblastic Leukemia (Erythroleukemia) 01/2020
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2020
1	Multiple Myeloma 01/2020
1	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell) 01/2018
1	Thrombocytopenia (Thrombopenia) 01/2016

Drug/Important Bio-Agent (IBA)

18	Pharmaceutical PreparationsIBA 01/2022 - 12/2003
10	Proteins (Proteins, Gene)FDA Link 01/2018 - 12/2003
10	N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)IBA 03/2016 - 05/2008
9	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 03/2005
8	GlucocorticoidsIBA 01/2020 - 03/2005
6	Vincristine (Oncovin)FDA LinkGeneric 09/2015 - 06/2002
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2014
5	Histone Deacetylase InhibitorsIBA 01/2022 - 09/2009
5	Biological ProductsIBA 01/2016 - 06/2002
4	RNA (Ribonucleic Acid)IBA 11/2020 - 08/2006
4	Phosphotransferases (Kinase)IBA 01/2020 - 12/2003
3	Histone Deacetylases (Histone Deacetylase)IBA 01/2022 - 10/2010
3	ChromatinIBA 01/2022 - 12/2018
3	Drug CombinationsIBA 01/2022 - 09/2009
3	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2019 - 01/2015
3	ProdrugsIBA 01/2019 - 06/2015
3	LigandsIBA 07/2016 - 03/2005
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 07/2016 - 05/2007
3	navitoclaxIBA 01/2016 - 03/2010
3	Asparaginase (Elspar)FDA Link 09/2015 - 09/2007
3	Vorinostat FDA Link 01/2015 - 09/2009
3	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2014 - 10/2010
3	ABT-737IBA 11/2013 - 09/2007
3	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 10/2010 - 03/2005
2	CBLC137IBA 01/2022 - 01/2020
2	PanobinostatIBA 01/2022 - 01/2016
2	Small Interfering RNA (siRNA)IBA 10/2021 - 11/2007
2	Dynamins (Dynamin)IBA 02/2021 - 12/2020
2	OT-82IBA 01/2020 - 01/2020
2	MLN 8237IBA 01/2019 - 11/2011
2	PolymersIBA 01/2019 - 02/2008
2	Messenger RNA (mRNA)IBA 01/2019 - 03/2014
2	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 04/2013
2	birinapantIBA 02/2016 - 01/2016
2	Tyrosine (L-Tyrosine)FDA Link 01/2016 - 06/2008
2	PR-104AIBA 09/2015 - 03/2014
2	Daunorubicin (Cerubidine)FDA LinkGeneric 07/2015 - 01/2015
2	Cyclin-Dependent Kinase Inhibitor p16IBA 04/2013 - 11/2006
1	Histone MethyltransferasesIBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	Immunoglobulin FragmentsIBA 11/2021
1	Thymic Stromal LymphopoietinIBA 11/2021
1	Cytokine Receptors (Cytokine Receptor)IBA 11/2021
1	ruxolitinibIBA 11/2021
1	Long Noncoding RNAIBA 10/2021
1	Lipid NanoparticlesIBA 10/2021
1	Transcription Factors (Transcription Factor)IBA 01/2021
1	Auranofin (Ridaura)FDA Link 01/2021
1	CateninsIBA 01/2021
1	lambda Spi-1IBA 01/2021
1	GTP Phosphohydrolases (GTPases)IBA 12/2020
1	dynole 34-2IBA 12/2020
1	Protein Kinases (Protein Kinase)IBA 01/2020
1	Complement System Proteins (Complement)IBA 01/2020
1	Clofarabine (Clolar)FDA Link 01/2020
1	proto-oncogene proteins pimIBA 01/2020
1	NAD (NADH)IBA 01/2020
1	VTP50469IBA 12/2019
1	romidepsin (FK228)FDA Link 01/2019
1	Sulfhydryl Compounds (Thiols)IBA 01/2019
1	monomethoxypolyethylene glycol (MPEG)IBA 01/2019
1	AntibodiesIBA 01/2019
1	nelarabine (506U78)FDA Link 01/2019
1	diethylene glycolIBA 01/2019
1	Protein Isoforms (Isoforms)IBA 01/2019
1	PND 1186IBA 01/2017
1	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2017
1	Antineoplastic Agents (Antineoplastics)IBA 10/2016
1	Tyrosine Kinase InhibitorsIBA 07/2016
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 07/2016
1	fms-Like Tyrosine Kinase 3IBA 07/2016
1	dinaciclibIBA 03/2016
1	purineIBA 03/2016
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2016
1	PhosphotyrosineIBA 01/2016
1	N-Myc Proto-Oncogene ProteinIBA 01/2016
1	Oncogene Proteins (Oncogene Protein)IBA 01/2016

Therapy/Procedure

21	Therapeutics 01/2022 - 05/2004
11	Drug Therapy (Chemotherapy) 01/2022 - 11/2007
2	Precision Medicine 01/2022 - 11/2020
1	Heterologous Transplantation (Xenotransplantation) 01/2022